Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The companies discussed their plans to change the one-test, one-drug companion diagnostic paradigm at the Personalized and Precision Medicine conference this week.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.
The data, presented at AACR by researchers from Novartis and Foundation Medicine, show that targeted NGS panels can be used to predict genome-wide mutational load.
Thermo Fisher will develop a companion diagnostic for multiple drugs under development for non-small cell lung cancer using its Ion PGM Dx and Oncomine assays.
The deal gives Arrowhead access to technologies developed by Novartis, a license to Alnylam intellectual property, and a pipeline of three preclinical RNAi drug candidates.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.